These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 30543575)

  • 1. Participation in a population-based screening for colorectal cancer using the faecal immunochemical test decreases mortality in 5 years.
    Idigoras Rubio I; Arana-Arri E; Portillo Villares I; Bilbao Iturribarrria I; Martínez-Indart L; Imaz-Ayo N; de la Cruz M; de Castro V; López de Munain A; Torrejón Perez I; Gutiérrez-Ibarluzea I
    Eur J Gastroenterol Hepatol; 2019 Feb; 31(2):197-204. PubMed ID: 30543575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.
    van der Vlugt M; Grobbee EJ; Bossuyt PMM; Bos A; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
    Gastroenterology; 2017 Aug; 153(2):439-447.e2. PubMed ID: 28483499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age-adapted Variation in Screening Interval of Fecal Immunochemical Test May Improve its Participation and Colonoscopy Acceptance.
    Kwak MS; Cha JM; Yoon JY; Jeon JW; Shin HP; Joo KR; Lee JI
    J Clin Gastroenterol; 2017 Oct; 51(9):825-830. PubMed ID: 27824639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Equivalency of fecal immunochemical tests and colonoscopy in familial colorectal cancer screening.
    Quintero E; Carrillo M; Gimeno-García AZ; Hernández-Guerra M; Nicolás-Pérez D; Alonso-Abreu I; Díez-Fuentes ML; Abraira V
    Gastroenterology; 2014 Nov; 147(5):1021-30.e1; quiz e16-7. PubMed ID: 25127679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interval cancers using a quantitative faecal immunochemical test (FIT) for haemoglobin when colonoscopy capacity is limited.
    Digby J; Fraser CG; Carey FA; Lang J; Stanners G; Steele RJ
    J Med Screen; 2016 Sep; 23(3):130-4. PubMed ID: 26589788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association Between Concentrations of Hemoglobin Determined by Fecal Immunochemical Tests and Long-term Development of Advanced Colorectal Neoplasia.
    Grobbee EJ; Schreuders EH; Hansen BE; Bruno MJ; Lansdorp-Vogelaar I; Spaander MCW; Kuipers EJ
    Gastroenterology; 2017 Nov; 153(5):1251-1259.e2. PubMed ID: 28760383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of High-performance Biomarker Tests vs Fecal Immunochemical Test for Noninvasive Colorectal Cancer Screening.
    Lansdorp-Vogelaar I; Goede SL; Bosch LJW; Melotte V; Carvalho B; van Engeland M; Meijer GA; de Koning HJ; van Ballegooijen M
    Clin Gastroenterol Hepatol; 2018 Apr; 16(4):504-512.e11. PubMed ID: 28733262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repeated screening with fecal immunochemical tests reduced the incidence of colorectal cancers in Saga, Japan.
    Sakata N; Sakata Y; Shimoda R; Sakata H; Iwakiri R; Fujimoto K; Mizuguchi M; Irie H; Shimoda Y; Noshiro H
    Hepatogastroenterology; 2014; 61(133):1224-8. PubMed ID: 25436287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Occurrence and characteristics of faecal immunochemical screen-detected cancers vs non-screen-detected cancers: Results from a Flemish colorectal cancer screening programme.
    van de Veerdonk W; Hoeck S; Peeters M; Van Hal G; Francart J; De Brabander I
    United European Gastroenterol J; 2020 Mar; 8(2):185-194. PubMed ID: 32213071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term performance of colorectal cancerscreening programmes based on the faecal immunochemical test.
    Zorzi M; Hassan C; Capodaglio G; Fedato C; Montaguti A; Turrin A; Rosano A; Monetti D; Stocco C; Baracco S; Russo F; Repici A; Rugge M
    Gut; 2018 Dec; 67(12):2124-2130. PubMed ID: 29101260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population-based screening for colorectal cancer using an immunochemical faecal occult blood test: a comparison of two invitation strategies.
    Van Roosbroeck S; Hoeck S; Van Hal G
    Cancer Epidemiol; 2012 Oct; 36(5):e317-24. PubMed ID: 22560885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of the faecal immunochemical test on colorectal cancer survival.
    Gutierrez-Stampa MA; Aguilar V; Sarasqueta C; Cubiella J; Portillo I; Bujanda L
    BMC Cancer; 2020 Jul; 20(1):616. PubMed ID: 32611328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interval cancer after two rounds of a Swedish population-based screening program using gender-specific cut-off levels in fecal immunochemical test.
    Ribbing Wilén H; Blom J
    J Med Screen; 2024 Mar; 31(1):8-14. PubMed ID: 37455444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Colorectal and interval cancers of the Colorectal Cancer Screening Program in the Basque Country (Spain).
    Portillo I; Arana-Arri E; Idigoras I; Bilbao I; Martínez-Indart L; Bujanda L; Gutierrez-Ibarluzea I
    World J Gastroenterol; 2017 Apr; 23(15):2731-2742. PubMed ID: 28487610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tests and investigations for colorectal cancer screening.
    Carroll MR; Seaman HE; Halloran SP
    Clin Biochem; 2014 Jul; 47(10-11):921-39. PubMed ID: 24769265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Faecal haemoglobin concentration influences risk prediction of interval cancers resulting from inadequate colonoscopy quality: analysis of the Taiwanese Nationwide Colorectal Cancer Screening Program.
    Chiu SY; Chuang SL; Chen SL; Yen AM; Fann JC; Chang DC; Lee YC; Wu MS; Chou CK; Hsu WF; Chiou ST; Chiu HM
    Gut; 2017 Feb; 66(2):293-300. PubMed ID: 26515543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Colorectal cancer incidence, mortality, tumour characteristics, and treatment before and after introduction of the faecal immunochemical testing-based screening programme in the Netherlands: a population-based study.
    Breekveldt ECH; Lansdorp-Vogelaar I; Toes-Zoutendijk E; Spaander MCW; van Vuuren AJ; van Kemenade FJ; Ramakers CRB; Dekker E; Nagtegaal ID; Krul MF; Kok NFM; Kuhlmann KFD; Vink GR; van Leerdam ME; Elferink MAG;
    Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):60-68. PubMed ID: 34822762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the colorectal cancer screening Programme in the Basque Country (Spain) and its effectiveness based on the Miscan-colon model.
    Idigoras I; Arrospide A; Portillo I; Arana-Arri E; Martínez-Indart L; Mar J; de Koning HJ; Lastra R; Soto-Gordoa M; van der Meulen M; Lansdorp-Vogelaar I
    BMC Public Health; 2017 Aug; 18(1):78. PubMed ID: 28764731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fecal Immunochemical Test Program Performance Over 4 Rounds of Annual Screening: A Retrospective Cohort Study.
    Jensen CD; Corley DA; Quinn VP; Doubeni CA; Zauber AG; Lee JK; Zhao WK; Marks AR; Schottinger JE; Ghai NR; Lee AT; Contreras R; Klabunde CN; Quesenberry CP; Levin TR; Mysliwiec PA
    Ann Intern Med; 2016 Apr; 164(7):456-63. PubMed ID: 26811150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Colorectal cancer in a second round after a negative faecal immunochemical test.
    Bujanda L; Sarasqueta C; Castells A; Pellisé M; Cubiella J; Gil I; Cosme A; Arana-Arri E; Mar I; Idigoras I; Portillo I;
    Eur J Gastroenterol Hepatol; 2015 Jul; 27(7):813-8. PubMed ID: 25856688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.